【摘要】：目的研究脾多肽聯(lián)合布地奈德霧化吸入對慢性阻塞性肺疾病急性加重期(AECOPD)患者肺功能及動脈血氣指標的影響。方法 AECOPD患者84例隨機分組,各42例。對照組予以布地奈德霧化吸入治療,觀察組予以脾多肽+布地奈德霧化吸入治療。比較兩組臨床療效,治療前后用力肺活量(FVC)、1 s用力呼氣容積(FEV1)、FEV1/FVC及動脈二氧化碳分壓(PaCO_2)、動脈血氧分壓(PaO_2)]變化。結果觀察組臨床治療總有效率92.86%高于對照組71.43%(P0.05);治療后觀察組FVC、FEV1、FEV1/FVC高于對照組(P0.05);PaCO_2低于對照組、Pa O_2高于對照組(P0.05)。結論聯(lián)合脾多肽和布地奈德霧化吸入用于AECOPD患者,可改善肺功能及動脈血氣指標,療效顯著。
[Abstract]:Objective to study the effect of spleen polypeptide combined with budesonide atomization inhalation on pulmonary function and arterial blood gas in patients with acute exacerbation of chronic obstructive pulmonary disease (AECOPD). Methods 84 patients with AECOPD were randomly divided into two groups, 42 patients each. The control group was treated with budesonide atomization inhalation, and the observation group was treated with spleen polypeptide budesonide atomization inhalation. The changes of forced vital capacity (FVC), 1 s forced breath volume (FEV1), FEV1/FVC, arterial partial pressure of carbon dioxide (PaCO_2) and arterial partial pressure of oxygen (PaO_2) were compared between the two groups before and after treatment. Results the total effective rate of clinical treatment in the observation group was 92.86%, which was higher than that in the control group (P 0.05), and the FVC,FEV1,FEV1/FVC in the observation group was higher than that in the control group after treatment (P 0.05). PaCO_2 was lower than that of the control group, and Pa O 鈮，

本文編號：2482617